Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019
Abstract Background Myotonic dystrophy (DM) is a rare, inherited disorder with multi-systemic effects that impact the skeletal muscles, eyes, heart, skin and gastrointestinal, endocrine, respiratory, and central nervous systems. DM is divided into two subtypes: DM1 can present from early childhood t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-02-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-022-02241-9 |
| _version_ | 1818501042419007488 |
|---|---|
| author | Sarah J. Howe David Ladipus Michael Hull Jason Yeaw Tanya Stevenson Jacinda B. Sampson |
| author_facet | Sarah J. Howe David Ladipus Michael Hull Jason Yeaw Tanya Stevenson Jacinda B. Sampson |
| author_sort | Sarah J. Howe |
| collection | DOAJ |
| description | Abstract Background Myotonic dystrophy (DM) is a rare, inherited disorder with multi-systemic effects that impact the skeletal muscles, eyes, heart, skin and gastrointestinal, endocrine, respiratory, and central nervous systems. DM is divided into two subtypes: DM1 can present from early childhood through adulthood and also has a congenital form (cDM) while DM2 typically manifests during mid-adulthood. Both forms are progressive with no approved treatments, and unmet need for disease-modifying therapies remains high. This study interrogated health insurance claims data to explore the clinical experience, healthcare resource utilization (HCRU), and all-cause costs for DM. Results A total of 8541 patients with DM and 242 patients with cDM and their matched controls were selected from a database of over 200 million claimants. HCRU and all-cause costs, including pharmacy, outpatient, and inpatient services, were analyzed across four years in 12-month follow-up periods. Mean all-cause costs per DM patient were high in each of the four periods (range $14,640–$16,704) and showed a steady increase from 13 to 23 months on, while the control group mean costs declined from $9671 in the first 12 months after the index event, to approach the US population average ($5193) over time. For cDM, the highest mean costs were in the first 12-months ($66,496 vs. $2818 for controls), and remained high (above $17,944) across all subsequent periods, while control mean costs approached $0. For DM and cDM, HCRU was higher compared to controls across all study periods and all-cause healthcare costs were mostly driven by inpatient and outpatient encounters. Analysis of all diagnosis codes over the study period (comorbidities) demonstrated an elevated comorbidity profile consistent with the clinical profile of DM. Conclusions This study is among the first to utilize claims data to increase understanding of the clinical experience and health economic outcomes associated with DM. The markedly elevated HCRU patterns and comorbidity profile presented here add to the broad body of scientific and clinical knowledge on DM. These insights can inform clinical care and support the development of disease modifying and/or symptom-targeting therapies that address the multi-systemic, progressive nature of DM. |
| first_indexed | 2024-12-10T20:50:49Z |
| format | Article |
| id | doaj.art-22497f593213445b9148842f1d1e33e3 |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-12-10T20:50:49Z |
| publishDate | 2022-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-22497f593213445b9148842f1d1e33e32022-12-22T01:34:05ZengBMCOrphanet Journal of Rare Diseases1750-11722022-02-0117111310.1186/s13023-022-02241-9Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019Sarah J. Howe0David Ladipus1Michael Hull2Jason Yeaw3Tanya Stevenson4Jacinda B. Sampson5Marigold FoundationLapidusData Inc.IQVIAIQVIAMyotonic Dystrophy FoundationStanford UniversityAbstract Background Myotonic dystrophy (DM) is a rare, inherited disorder with multi-systemic effects that impact the skeletal muscles, eyes, heart, skin and gastrointestinal, endocrine, respiratory, and central nervous systems. DM is divided into two subtypes: DM1 can present from early childhood through adulthood and also has a congenital form (cDM) while DM2 typically manifests during mid-adulthood. Both forms are progressive with no approved treatments, and unmet need for disease-modifying therapies remains high. This study interrogated health insurance claims data to explore the clinical experience, healthcare resource utilization (HCRU), and all-cause costs for DM. Results A total of 8541 patients with DM and 242 patients with cDM and their matched controls were selected from a database of over 200 million claimants. HCRU and all-cause costs, including pharmacy, outpatient, and inpatient services, were analyzed across four years in 12-month follow-up periods. Mean all-cause costs per DM patient were high in each of the four periods (range $14,640–$16,704) and showed a steady increase from 13 to 23 months on, while the control group mean costs declined from $9671 in the first 12 months after the index event, to approach the US population average ($5193) over time. For cDM, the highest mean costs were in the first 12-months ($66,496 vs. $2818 for controls), and remained high (above $17,944) across all subsequent periods, while control mean costs approached $0. For DM and cDM, HCRU was higher compared to controls across all study periods and all-cause healthcare costs were mostly driven by inpatient and outpatient encounters. Analysis of all diagnosis codes over the study period (comorbidities) demonstrated an elevated comorbidity profile consistent with the clinical profile of DM. Conclusions This study is among the first to utilize claims data to increase understanding of the clinical experience and health economic outcomes associated with DM. The markedly elevated HCRU patterns and comorbidity profile presented here add to the broad body of scientific and clinical knowledge on DM. These insights can inform clinical care and support the development of disease modifying and/or symptom-targeting therapies that address the multi-systemic, progressive nature of DM.https://doi.org/10.1186/s13023-022-02241-9Myotonic dystrophy (DM)Healthcare resource utilization (HCRU)Insurance claims databaseDystrophyRare diseaseCongenital myotonic dystrophy |
| spellingShingle | Sarah J. Howe David Ladipus Michael Hull Jason Yeaw Tanya Stevenson Jacinda B. Sampson Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 Orphanet Journal of Rare Diseases Myotonic dystrophy (DM) Healthcare resource utilization (HCRU) Insurance claims database Dystrophy Rare disease Congenital myotonic dystrophy |
| title | Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 |
| title_full | Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 |
| title_fullStr | Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 |
| title_full_unstemmed | Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 |
| title_short | Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019 |
| title_sort | healthcare resource utilization total costs and comorbidities among patients with myotonic dystrophy using u s insurance claims data from 2012 to 2019 |
| topic | Myotonic dystrophy (DM) Healthcare resource utilization (HCRU) Insurance claims database Dystrophy Rare disease Congenital myotonic dystrophy |
| url | https://doi.org/10.1186/s13023-022-02241-9 |
| work_keys_str_mv | AT sarahjhowe healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 AT davidladipus healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 AT michaelhull healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 AT jasonyeaw healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 AT tanyastevenson healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 AT jacindabsampson healthcareresourceutilizationtotalcostsandcomorbiditiesamongpatientswithmyotonicdystrophyusingusinsuranceclaimsdatafrom2012to2019 |